# | id | title | category | type | labeler | labeler act | last update | version | product(s) |
---|
1 | 0c3354b5-a1d8-4f98-ad55-2eafe4265c4e (view SPL) | These highlights do not include all the information needed to use Zemaira safely and effectively. See full prescribing information for Zemaira. Zemaira, Alpha1-Proteinase Inhibitor (Human)For Intravenous Use. Lyophilized Powder for Reconstitution.Initial U.S. Approval: 2003 | other | Plasma Derivative | Csl Behring Llc | MANUFACTURE | 2015-09-30 | 16 | 000537201 |
2 | 83473cbb-48e4-42a2-81b6-4c851423da7b (view SPL) | These highlights do not include all the information needed to use GLASSIA safely and effectively. See full prescribing information for GLASSIA.GLASSIA (Alpha1-Proteinase Inhibitor (Human)) Injection Solution- For Intravenous Use OnlyInitial U.S. Approval: July 2010 | other | Plasma Derivative | Baxter Healthcare Corporation | MANUFACTURE | 2014-03-20 | 16 | 009442884 |
3 | 91edab72-c889-470e-8315-1798b5548dca (view SPL) | These highlights do not include all the information needed to use PROLASTIN-C safely and effectively. See full prescribing information for PROLASTIN-C. PROLASTIN-C (Alpha1-Proteinase Inhibitor [Human])Lyophilized Powder for Solution for Injection For Intravenous UseInitial U.S. Approval: 1987 | other | Plasma Derivative | Grifols | MANUFACTURE | 2013-11-13 | 13 | 135330700, 135330701 |
4 | a9a5b46e-04da-41bd-bb5f-c4936b664fef (view SPL) | These highlights do not include all the information needed to use ARALAST NP safely and effectively. See full prescribing information for ARALAST NP.ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]For Intravenous Use. Lyophilized Powder for Solution for Injection Initial U.S. Approval: 2002 | other | Plasma Derivative | Baxter Healthcare Corporation | MANUFACTURE | 2014-03-17 | 4 | 009442814, 009442815 |